On 3 June, Alzheimer Europe (AE) hosted a Company Round Table meeting in Brussels, bringing together company representatives from Anavex, Biogen, BMS, Danone (Nutricia), Eisai, Eli Lilly, EFPIA, Johnson & Johnson, Novo Nordisk and Roche, alongside AE staff and members from 22 national Alzheimer organisations. The event was moderated by AE chairperson Rosário Zincke dos Reis and featured four presentations. First, Cindy Birck, AE Project Officer, gave an update on our Clinical Trials Watch, an online database providing accessible and up-to-date information on clinical trials that are investigating drugs for Alzheimer’s disease and/or dementia. Next, Owen Miller, AE Project Officer, shared some updates on EU policy developments, noting the re-launch of the European Alzheimer’s Alliance (EAA) on World Alzheimer’s Day, 21 September 2024.
The EAA now comprises 89 members of the EAA from 22 countries. The next presentation was given by Angela Bradshaw, AE Director for Research, addressing advancements in anti-amyloid treatments, particularly focusing on the regulatory processes for lecanemab and donanemab in Europe. Then, Mario Possenti, AE Vice-Chairperson, and Angela Bradshaw gave a joint presentation, informing participants about Alzheimer Europe’s activities in 2025 including the annual conference. Finally, Lukas Duffner, AE Project Officer, presented the recent public opinion poll, launched by AE, aiming to examine attitudes towards dementia research participation and data sharing. We would like to thank our sponsors and members for participating in this meeting and we look forward to welcoming them to the next Company Round Table meeting, which will take place online on 17 September 2025.